EORTC 22071-24071

TPS197 Background: The clinical outcome of patients (pts) with resected HNSCC at high risk of recurrence remains poor. Disease free survival (DFS) at 5 years is around 40% after standard adjuvant chemoradiation (CRT). The use of anti-EGFR monoclonal antibodies combined with radiotherapy was shown to be effective in pts with HNSCC, and combination with CRT showed to be safe.METHODS: This open-label phase III randomized trial will investigate whether the addition of the anti-EGFR antibody panitumumab to adjuvant CRT significantly prolongs DFS in HNSCC at high risk of recurrence. Pts with high-risk HNSCC, due to the presence of close resection margins (